A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT03178552
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
1000 participants
INTERVENTIONAL
2017-09-22
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
NCT02272413
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06624059
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
NCT00410904
To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC
NCT05169801
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A: Alectinib 600 Milligrams (mg)
This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Enrollment to Cohort A is complete.
Alectinib
Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
Cohort B: Dose Finding Phase (DFP) Alectinib
This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose.
Enrollment to Cohort B is complete.
Alectinib
Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
Cohort B: Dose Expansion Phase (DEP) Alectinib
This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.
Enrollment to Cohort B is complete.
Alectinib
Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
Cohort C: Atezolizumab 1200 mg
This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.
Enrollment to Cohort C is complete.
Atezolizumab
Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
Cohort C: Pemetrexed, Cisplatin or Carboplatin
This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m\^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m\^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.
Enrollment to Cohort C is complete.
Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
Cisplatin
Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
Carboplatin
Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Cohort C: Gemcitabine, Cisplatin or Carboplatin
This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m\^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m\^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.
Enrollment to Cohort C is complete.
Cisplatin
Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
Carboplatin
Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Gemcitabine
Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
Cohort D: Entrectinib 600 Milligrams (mg)
This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Enrollment to Cohort D is complete.
Entrectinib
Participants will receive entrectinib 600 mg orally QD.
Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib
This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
Enrollment to Cohort E is complete.
Atezolizumab
Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
Cobimetinib
Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
Vemurafenib
Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed
This cohort includes participants with EGFR exon 20+ NSCLC. Participants will receive atezolizumab + bevacizumab + carboplatin + pemetrexed for 4 or 6 induction cycles (cycle = 21 days). After induction therapy, participants will continue maintenance treatment with atezolizumab + bevacizumab + pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Enrollment to Cohort F is complete.
Atezolizumab
Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
Carboplatin
Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Bevacizumab
Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
Cohort G: Divarasib or Docetaxel
Experimental: Cohort G: GDC-6036 or Docetaxel This cohort includes participants with KRAS G12C mutation. Participants will receive GDC-6036 PO QD or IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
New participants will no longer receive docetaxel.
Divarasib
Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
Docetaxel
Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
Cohort Z: Natural History Cohort
Participants with genomic profiles of interest that are not enrolled in the other cohorts will enter into natural history follow-up.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alectinib
Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
Atezolizumab
Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
Pemetrexed
Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
Cisplatin
Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
Carboplatin
Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Gemcitabine
Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
Entrectinib
Participants will receive entrectinib 600 mg orally QD.
Cobimetinib
Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
Vemurafenib
Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
Bevacizumab
Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
Divarasib
Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
Docetaxel
Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
* Measurable disease
* Adequate recovery from most recent systemic or local treatment for cancer
* Adequate organ function
* Life expectancy greater than or equal to (\>/=) 12 weeks
* For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception
Exclusion Criteria
* Women who are pregnant or lactating
* Symptomatic, untreated CNS metastases
* History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
* Known active or uncontrolled human immunodeficiency virus (HIV) infection
* Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
* Inability to comply with other requirements of the protocol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Davis
Sacramento, California, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
SCRI Florida Cancer Specialists South
Fort Myers, Florida, United States
Florida Cancer Specialist, North Region
St. Petersburg, Florida, United States
University of Kentucky
Lexington, Kentucky, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Weill Cornell Medical College-New York Presbyterian Hospital
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Oregon HSU
Portland, Oregon, United States
St. Luke's University Health network
Bethlehem, Pennsylvania, United States
Sarah Cannon Research Institute / Tennessee Oncology
Chattanooga, Tennessee, United States
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, , Argentina
Hospital Italiano
Buenos Aires, , Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, , Argentina
Royal North Shore Hospital
St Leonards, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Ashford Cancer Center Research
Kurralta Park, South Australia, Australia
UZ Brussel
Brussels, , Belgium
Cliniques Universitaires St-Luc
Brussels, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Instituto Nacional de Cancer - INCa
Rio de Janeiro, , Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
William Osler Health System Brampton Civic Hospital
Brampton, Ontario, Canada
London Health Sciences Centre · Victoria Hospital
London, Ontario, Canada
Lakeridge Health Center
Oshawa, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
IUCPQ (Hôpital Laval)
Québec, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Bradford Hill Centro de Investigaciones Clinicas
Recoleta, , Chile
Beijing Cancer Hospital
Beijing, , China
Jilin Cancer Hospital
Changchun, , China
Hunan Cancer Hospital
Changsha, , China
The second Xiangya hospital of central south university
Changsha, , China
Sichuan Cancer Hospital
Chengdu, , China
West China Hospital - Sichuan University
Chengdu, , China
The First Affiliated Hospital of Guangzhou Medical University Pharmacy
Guangzhou, , China
Zhejiang Cancer Hospital
Hangzhou, , China
Shandong Cancer Hospital
Jinan, , China
The Second Affiliated Hospital to Nanchang University
Nanchang, , China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, , China
Fudan Unviversity Shanghai Cancer Center
Shanghai, , China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, , China
Centre Oscar Lambret
Lille, , France
Centre Léon Bérard
Lyon, , France
Hôpital Européen Georges Pompidou
Paris, , France
Hopital Tenon
Paris, , France
CHU Poitiers
Poitiers, , France
Hopital Pontchaillou
Rennes, , France
CHU de Toulouse - Hôpital Larrey
Toulouse, , France
Klinikum Chemnitz gGmbH
Chemnitz, , Germany
Asklepios-Fachklinik Muenchen-Gauting
Gauting, , Germany
Thoraxklinik Heidelberg gGmbH
Heidelberg, , Germany
HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed
Wiesbaden, , Germany
Queen Mary Hospital
Hong Kong, , Hong Kong
Prince of Wales Hosp
Shatin, , Hong Kong
Soroka Medical Center
Beersheba, , Israel
Rambam Health Care Campus
Haifa, , Israel
Meir Medical Center
Kfar Saba, , Israel
Rabin MC
Petah Tikva, , Israel
Chaim Sheba Medical Center
Ramat Gan, , Israel
Sourasky / Ichilov Hospital; Dept. of Oncology
Tel Aviv, , Israel
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Napoli, Campania, Italy
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
Meldola, Emilia-Romagna, Italy
Irccs Centro Di Riferimento Oncologico (CRO)
Aviano, Friuli Venezia Giulia, Italy
Azienda Ospedaliera San Camillo Forlanini
Rome, Lazio, Italy
Asst Papa Giovanni XXIII
Bergamo, Lombardy, Italy
ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona
Cremona, Lombardy, Italy
Irccs Istituto Europeo di Oncologia (IEO)
Milan, Lombardy, Italy
Asst Di Monza
Monza, Lombardy, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Orbassano (TO), Piedmont, Italy
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
Bunkyō City, , Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Kanazawa University Hospital
Ishikawa, , Japan
Kanagawa Cancer Center
Kanagawa, , Japan
University Hospital Kyoto Prefectural University of Medicine
Kyoto, , Japan
Shikoku Cancer Center
Matsuyama, , Japan
Tohoku University Hospital
Miyagi, , Japan
Sendai Kousei Hospital
Miyagi, , Japan
Niigata University Medical & Dental Hospital
Niigata, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Kindai University Hospital
Osaka, , Japan
Saga University Hospital
Saga, , Japan
Shizuoka Cancer Center
Shizuoka, , Japan
Juntendo University Hospital
Tokyo, , Japan
The Cancer Institute Hospital of JFCR
Tokyo, , Japan
Kyorin University Hospital
Tokyo, , Japan
Fujita Health University Hospital
Toyoake-shi, , Japan
Wakayama Medical University Hospital
Wakayama, , Japan
National Hospital Organization Yamaguchi - Ube Medical Center
Yamaguchi, , Japan
Hospital Angeles Tijuana
Tijuana, Estado de Baja California, Mexico
Health Pharma Professional Research
Mexico City, Mexico CITY (federal District), Mexico
AVIX Investigación Clínica S.C
Monterrey, Nuevo León, Mexico
Oncologico Potosino
San Luis Potosí City, San Luis Potosí, Mexico
Auckland City Hospital
Auckland, , New Zealand
Hemato Oncología de Panamá Especializada
Panama City, , Panama
Hospital Nacional Edgardo Rebagliati Martins
Lima, , Peru
Instituto Nacional de Enfermedades Neoplasicas
Lima, , Peru
Instituto Peruano de Oncología y Radioterapia
Lima, , Peru
Clinica Ricardo Palma
San Isidro, , Peru
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gda?sk, , Poland
Krakowski Szpital Specjalistyczny im sw.Jana Pawla II
Krakow, , Poland
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
Olsztyn, , Poland
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
Otwock, , Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, , Poland
Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie
Warsaw, , Poland
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, Russia
Principal Military Clinical Hospital n.a. N.N. Burdenko
Moscow, Moscow Oblast, Russia
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
Saint Petersburg, Sankt-Peterburg, Russia
Clinical Oncology Dispensary
Omsk, , Russia
Clinical Center of Serbia
Belgrade, , Serbia
University Hospital Medical Center Bezanijska kosa
Belgrade, , Serbia
Institute for Pulmonary Diseases of Vojvodina
Kamenitz, , Serbia
Clinical Center Nis
Niš, , Serbia
National University Hospital
Singapore, , Singapore
National Cancer Centre
Singapore, , Singapore
National Cancer Center
Gyeonggi-do, , South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Yonsei University Health System/Severance Hospital
Seoul, , South Korea
Insititut Catala D'Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, LA Coruna, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Hospital General Univ. de Alicante
Alicante, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Clínic i Provincial
Barcelona, , Spain
ICO Badalona - Hospital Germans Trias i Pujol
Barcelona, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Hospital Ramon y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Centro Integral Oncologico Clara Campal
Madrid, , Spain
Hospital Universitario Puerta de Hierro
Madrid, , Spain
Hospital Quiron de Madrid
Madrid, , Spain
Hospital Regional Universitario Carlos Haya
Málaga, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
National Taiwan Uni Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation - Linkou
Taoyuan District, , Taiwan
Chulalongkorn Hospital
Bangkok, , Thailand
Ramathibodi Hospital
Bangkok, , Thailand
Faculty of Med. Siriraj Hosp.
Bangkok, , Thailand
Prince of Songkla University
Hat Yai, , Thailand
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
Adana, , Turkey (Türkiye)
Akdeniz University Medical Faculty; Medical Oncology Department
Antalya, , Turkey (Türkiye)
Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department
Edirne, , Turkey (Türkiye)
Medipol University Medical Faculty; Oncology Department
Istanbul, , Turkey (Türkiye)
Marmara University Pendik Training and Research Hospital; Medikal Onkoloji
Istanbul, , Turkey (Türkiye)
Medikal Park Izmir Hospital
Kar??yaka, , Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
Sihhiye/Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19.
Wang HY, Ho CC, Lin YT, Liao WY, Chen CY, Shih JY, Yu CJ. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. JCO Precis Oncol. 2024 Jan;8:e2300314. doi: 10.1200/PO.23.00314.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-000076-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
BO29554
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.